MyMD Pharmaceuticals (MYMD) Competitors $0.22 +0.00 (+1.27%) As of 04/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock MYMD vs. ALLR, CMMB, SLGL, EQ, UBX, CING, EDSA, NAII, LPCN, and LPTXShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Allarity Therapeutics (ALLR), Chemomab Therapeutics (CMMB), Sol-Gel Technologies (SLGL), Equillium (EQ), Unity Biotechnology (UBX), Cingulate (CING), Edesa Biotech (EDSA), Natural Alternatives International (NAII), Lipocine (LPCN), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Allarity Therapeutics Chemomab Therapeutics Sol-Gel Technologies Equillium Unity Biotechnology Cingulate Edesa Biotech Natural Alternatives International Lipocine Leap Therapeutics Allarity Therapeutics (NASDAQ:ALLR) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking. Does the MarketBeat Community favor ALLR or MYMD? Allarity Therapeutics received 1 more outperform votes than MyMD Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% MyMD PharmaceuticalsN/AN/A Which has higher valuation & earnings, ALLR or MYMD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/AMyMD PharmaceuticalsN/AN/A-$4MN/AN/A Do insiders and institutionals have more ownership in ALLR or MYMD? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ALLR or MYMD more profitable? MyMD Pharmaceuticals' return on equity of -179.05% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% MyMD Pharmaceuticals N/A -179.05%-108.14% Which has more risk & volatility, ALLR or MYMD? Allarity Therapeutics has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Does the media favor ALLR or MYMD? In the previous week, Allarity Therapeutics had 2 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for MyMD Pharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 1.14 beat Allarity Therapeutics' score of 0.79 indicating that MyMD Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MyMD Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMyMD Pharmaceuticals beats Allarity Therapeutics on 5 of the 9 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$528,000.00$2.35B$5.56B$7.82BDividend YieldN/A0.75%5.11%4.22%P/E RatioN/A6.4322.5718.48Price / SalesN/A50.54395.64103.60Price / CashN/A15.7538.1834.62Price / Book0.033.646.774.25Net Income-$4M-$65.73M$3.22B$248.23M7 Day Performance25.24%1.10%1.46%0.89%1 Month Performance-36.34%-1.61%3.98%3.53%1 Year Performance-93.04%-10.81%16.14%5.09% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.22+1.3%N/A-92.8%$528,000.00N/A0.006Positive NewsHigh Trading VolumeALLRAllarity Therapeutics0.3009 of 5 stars$0.99-3.8%N/A-96.9%$16.86MN/A0.0010CMMBChemomab Therapeutics3.5842 of 5 stars$1.17+0.9%$9.00+669.2%+92.9%$16.80MN/A-1.1720Upcoming EarningsShort Interest ↓News CoverageSLGLSol-Gel Technologies2.3711 of 5 stars$0.60+2.1%$5.00+737.5%+6.7%$16.63M$11.71M-1.7650News CoverageGap DownEQEquillium2.7926 of 5 stars$0.47+2.2%$3.00+545.2%-71.8%$16.61M$41.10M-3.3240Upcoming EarningsShort Interest ↓UBXUnity Biotechnology4.1222 of 5 stars$0.98+4.5%$5.33+443.1%-26.6%$16.56M$240,000.00-0.7560Analyst RevisionNews CoverageCINGCingulate2.4774 of 5 stars$4.16+2.2%$30.67+637.2%+350.8%$16.40MN/A-0.2820Short Interest ↑News CoverageNegative NewsGap DownEDSAEdesa Biotech3.1025 of 5 stars$2.33-2.1%$21.00+801.3%-47.6%$16.29MN/A-1.2520Short Interest ↓NAIINatural Alternatives International0.8409 of 5 stars$2.62+0.4%N/A-52.0%$16.24M$121.85M-2.03290Gap DownLPCNLipocine2.4982 of 5 stars$3.01flat$10.00+232.2%-28.4%$16.10M$11.20M-3.9610Upcoming EarningsAnalyst ForecastNews CoverageLPTXLeap Therapeutics2.6186 of 5 stars$0.39+7.3%$4.92+1,173.7%-86.5%$15.93MN/A-0.2040Gap Up Related Companies and Tools Related Companies ALLR Alternatives CMMB Alternatives SLGL Alternatives EQ Alternatives UBX Alternatives CING Alternatives EDSA Alternatives NAII Alternatives LPCN Alternatives LPTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYMD Stock Free MYMD Stock Alerts